首页 Catalent(usCTLT)-基本信息

Catalent(usCTLT)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:110.12

最高价:110.62

成交量:241129.0

昨收价:109.36

最低价:108.82

最新价:110.3

行情图标
概要信息

英文名称:Catalent


行业:医疗


简介:Catalent, Inc.于2007年4月成立。Catalent是全球领先的提供先进传输技术和开发解决方案的药物公司,主要的生物制品是消费者放心使用的健康产品


电话:1-732-5376200


最新量化综合结论
百科信息
  • 相关网站
  • 员工交易记录
  • 持股信息
  • 领导人信息

交易日期 交易人 职位 类型 交易份额 价格
2017-07-31 Dolan (Christine) Officer Sell 745 34.85
2017-07-30 Dolan (Christine) Officer Sell 734 34.97
2017-07-30 Downie (William) Officer Sell 2211 34.97
2017-07-30 Miyamoto Lance Officer Sell 1412 34.97
2017-07-30 Walsh (Matthew M) Chief Financial Officer Sell 3230 34.97
2017-07-30 Joseph Wetteny Officer Sell 712 34.97
2017-07-30 Chiminski (John R) Chief Executive Officer Sell 3816 34.97
2017-07-30 Littlejohns Barry Officer Sell 1332 34.97
2017-07-30 Gunther (Scott) Officer Sell 845 34.97
2017-07-30 Maselli (Alessandro) Officer Sell 703 34.97
2017-07-23 Joseph Wetteny Officer Buy 2221 --
2017-07-23 Dolan (Christine) Officer Buy 1888 --
2017-07-23 Downie (William) Officer Buy 2777 --
2017-07-23 Gunther (Scott) Officer Buy 1888 --
2017-07-23 Gennadios (Aristippos) Officer Buy 2499 --
2017-07-23 Fasman (Steven L) General Counsel Buy 3610 --
2017-07-23 Littlejohns Barry Officer Buy 2777 --
2017-07-23 Walsh (Matthew M) Chief Financial Officer Buy 5275 --
2017-07-23 Maselli (Alessandro) Officer Buy 1999 --
2017-07-23 Miyamoto Lance Officer Buy 2916 --
2017-07-23 Chiminski (John R) Chief Executive Officer Buy 19989 --
2017-06-08 Walsh (Matthew M) Chief Financial Officer Sell 2759 --
2017-06-07 Walsh (Matthew M) Chief Financial Officer Sell 24989 --
2017-06-07 Walsh (Matthew M) Chief Financial Officer Buy 54277 10.71
2017-06-07 Walsh (Matthew M) Chief Financial Officer Buy 20374 14.86
2017-06-07 Walsh (Matthew M) Chief Financial Officer Sell 46903 37.01
2017-04-24 Johnson Sharon Officer Sell 512 29.00
2017-04-24 Johnson Sharon Officer Sell 891 29.00
2017-04-24 Johnson Sharon Officer Buy 31150 10.71
2017-04-24 Johnson Sharon Officer Sell 60 29.00
第 页, 共 4 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Schroder Investment Management Group 2573147 1.77% -220391 -7.89% 2019-03-31
William Blair Investment Management, LLC 4086922 2.80% -4435 -0.11% 2019-03-31
J.P. Morgan Investment Management, Inc. 5133134 3.52% -52592 -1.01% 2019-07-31
BlackRock Fund Advisors 11753784 8.07% -198451 -1.66% 2019-07-31
Vanguard Group Inc 13488574 9.26% 306246 2.32% 2019-03-31
BlackRock Inc 13918974 9.55% 1023315 7.94% 2019-03-31
HHG PLC 17503223 12.01% 2620352 17.61% 2019-03-31
Janus Capital Management LLC 18171672 12.47% -113287 -0.62% 2019-07-31
T. Rowe Price Associates, Inc. 23092718 15.85% 772059 3.46% 2019-03-31
Vanguard Investments Australia Ltd 4070537 2.79% 2280 0.06% 2019-07-31
Champlain Investment Partners, LLC 3913500 2.69% 74670 1.95% 2019-03-31
State Street Corporation 3795021 2.60% 36856 0.98% 2019-03-31
Jackson National Asset Management LLC 2844213 1.95% 59741 2.15% 2019-07-31
Fidelity Management and Research Company 2923820 2.01% -98067 -3.25% 2019-03-31
Brown Investment Advisory Incorporated 2946067 2.02% 61651 2.14% 2019-03-31
Brown Advisory Holdings Inc 2952362 2.03% 61651 2.13% 2019-03-31
Franklin Advisers, Inc. 3407102 2.34% -- -- 2019-03-31
Franklin Resources Inc 3407102 2.34% -- -- 2019-03-31
FMR Inc 3464920 2.38% -113167 -3.16% 2019-03-31
Fidelity Management & Research Company 3582717 2.46% -1453323 -28.86% 2019-07-31
BlackRock Asset Management Canada Ltd 17173210 11.79% 3456 0.02% 2019-05-31
Geode Capital Management, LLC 2845720 1.95% 1531267 116.49% 2018-12-31
JPMorgan Chase & Co 7976203 5.48% 1819020 29.54% 2018-09-30
Schroder Investment Management North America Inc. 2888032 1.99% -199106 -6.45% 2018-06-30
BlackRock Institutional Trust Company NA 4355479 3.00% -248653 -5.40% 2018-06-30
American Century Investment Management, Inc 3052515 2.10% 183880 6.41% 2018-06-30
Franklin Advisers Inc 3405819 2.55% 5819 0.17% 2018-06-30
Citadel Advisors Llc 1871328 1.40% 74540 4.15% 2018-06-30
GW&K Investment Management, LLC 1894003 1.42% -9861 -0.52% 2018-06-30
J.P. Morgan Investment Management Inc 5152755 3.86% 1235831 31.55% 2018-06-30
State Street Corp 3707349 2.78% -1030881 -21.76% 2018-06-30
American Century Inv Mgt Inc 3052515 2.29% 183880 6.41% 2018-06-30
Earnest Partners LLC 2540466 1.90% 41692 1.67% 2018-03-31
Delaware Management Business Trust 2349059 1.76% 472228 25.16% 2018-06-30
Viking Global Investors LP 2323062 1.74% 808689 53.40% 2018-06-30
Northern Trust Investments N A 2028672 1.52% 2194 0.11% 2018-03-31
State Street Global Markets, LLC 1533616 1.15% 26672 1.77% 2018-04-30
Dimensional Fund Advisors, Inc. 1334134 1.00% -44374 -3.22% 2017-12-31
Millennium Management LLC 1981973 1.49% 1894831 2174.42% 2017-09-30
Macquarie Investment Management Limited 2069323 1.56% 2069323 -- 2017-09-30
Renaissance Technologies Corp 1848300 1.39% 1190400 180.94% 2017-09-30
Schroder Investment Management Ltd 1602272 1.29% 4850 0.30% 2017-11-30
Goldman Sachs Asset Management LP 1630488 1.30% -223486 -12.05% 2017-06-30
UBS Asset Mgmt Americas Inc 3361975 2.69% -370846 -9.93% 2016-09-30
Genstar IV GP LLC 2862691 2.30% -4182210 -59.37% 2015-12-31
Fidelity Institutional Asset Management 2599535 2.08% 795975 44.13% 2016-09-30
Vaughan Nelson Scarbrgh & Mccullough LP 2235375 1.79% -225200 -9.15% 2016-12-31
BlackRock Advisors LLC 2316187 1.86% -360559 -13.47% 2016-09-30
LAURION CAPITAL MANAGEMENT LP 2005074 1.61% 1531074 323.01% 2016-09-30
Invesco Advisers, Inc 1797665 1.44% 15686 0.88% 2016-09-30
Goldman, Sachs & Co. 1556069 1.25% 696801 81.09% 2016-09-30
BlackRock, Inc. 12922825 8.00% 397893782 0.10% 1999-11-30
T Rowe Price Associates, Inc. 17690798 8.00% 544699670 0.10% 1999-11-30
Blackstone 25886244 8.00% 797037453 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BlackRock Mid-Cap Growth Equity Port 1253259 0.86% -- -- 2019-06-30
Franklin Growth Fund 3365622 2.31% -- -- 2019-06-30
Vanguard Small Cap Index 3724443 2.56% -74858 -1.97% 2019-06-30
Vanguard Total Stock Market Index Fund 4036127 2.77% 694 0.02% 2019-06-30
Janus Henderson Enterprise Fund 4239328 2.91% -- -- 2019-06-30
Janus Mid Cap Growth Tr 4239328 2.91% -- -- 2019-06-30
iShares Core S&P Mid-Cap ETF 4282114 2.94% 8260 0.19% 2019-07-30
Janus Henderson Triton Fund 6114215 4.20% -- -- 2019-06-30
T. Rowe Price Mid-Cap Growth Fund 8000000 5.49% -- -- 2019-06-30
Champlain Mid Cap Fund, LLC 2377635 1.63% 1800 0.08% 2019-06-30
JPMorgan Small Cap Equity Fund 2253022 1.55% -- -- 2019-06-30
Vanguard Small Cap Growth Index Fund 2135018 1.47% -21545 -1.00% 2019-06-30
JPMorgan Growth Advantage Fund 1303000 0.89% -- -- 2019-06-30
JNL/T. Rowe Price Mid-Cap Growth Fund 1502000 1.03% 55000 3.80% 2019-03-31
T. Rowe Price Small-Cap Stock Fund 1512138 1.04% -24900 -1.62% 2019-06-30
MassMutual Select Mid Cap Growth Fund 1513000 1.04% -29000 -1.88% 2019-06-30
Janus Henderson Venture Fund 1629958 1.12% -- -- 2019-06-30
SPDR 1659284 1.14% -12428 -0.74% 2019-06-30
T. Rowe Price Instl Mid-Cap Eq Gr Fd 1959000 1.34% -17000 -0.86% 2019-06-30
Vanguard Extended Market Index Fund 1999807 1.37% -17501 -0.87% 2019-06-30
T. Rowe Price New Horizons Fund 1647232 1.13% -75739 -4.40% 2019-03-31
Franklin Growth Fd 3365622 2.31% -- -- 2019-05-31
iShares Core MSCI AllCntry Wld exCan ETF 4243931 2.91% -- -- 2019-05-23
iShares S&P US Mid-Cap ETF 4242281 2.91% -- -- 2019-05-30
iShares S&P US Mid-Cap ETF (CAD-Hedged) 4242281 2.91% -- -- 2019-05-30
iShares Core S&P US Total Market ETF 4242281 2.91% -- -- 2019-05-30
Vanguard Small Cap Index Fund 3806388 2.61% 27892 0.74% 2019-04-30
Fidelity 1212850 0.83% -- -- 2019-02-28
iShares Russell 2000 Growth ETF 1345818 0.92% 2320 0.17% 2018-06-21
Janus Henderson Global Life Sciences Fd 1103360 0.76% 927707 528.15% 2018-12-31
Champlain Mid Cap Fund 940000 0.65% 60000 6.82% 2018-10-31
William Blair Small-Mid Cap Growth Fund 1011969 0.70% 20800 2.10% 2018-11-30
iShares S&P Mid-Cap 400 Growth ETF 1276313 0.88% -5460 -0.43% 2018-11-30
T. Rowe Price Instl Mid-Cap Equity Gr 1484300 1.11% 48300 3.36% 2018-06-30
William Blair Small-Mid Cap Gr I 994069 0.69% 179100 21.98% 2018-07-31
JNL/T. Rowe Price Mid-Cap Growth B 1086000 0.81% -- -- 2018-06-30
T. Rowe Price Mid-Cap Growth 6000000 4.50% -- -- 2018-06-30
Janus Triton D 4391506 3.29% 267988 6.50% 2018-06-30
Vanguard Total Stock Mkt Idx 3590927 2.48% 234696 6.99% 2018-07-31
Franklin Growth Fund A 3400000 2.35% -- -- 2018-07-31
JPMorgan Small Cap Equity A 2509395 1.73% -- -- 2018-07-31
Vanguard Small Cap Growth Index Inv 2056406 1.42% 168748 8.94% 2018-07-31
Vanguard Extended Market Idx Inv 1895506 1.31% 152416 8.74% 2018-07-31
T. Rowe Price Small-Cap Stock 1456659 1.09% 31471 2.21% 2018-06-30
Janus Venture D 1383025 1.04% -- -- 2018-06-30
iShares S&P Mid-Cap 400 Growth 1299347 0.90% 12845 1.00% 2018-09-12
Champlain Small Company Fund 1251065 0.86% 77250 6.58% 2018-08-31
MassMutual Select Mid Cap Gr Eq II A 1153000 0.86% 115000 11.08% 2018-06-30
JPMorgan Growth Advantage A 1104400 0.76% 1104400 -- 2018-07-31
Harbor Small Cap Value Instl 797919 0.60% 20682 2.66% 2018-06-30
Champlain Mid Cap Adv 800000 0.60% 175000 28.00% 2018-04-30
Fidelity Advisor 791400 0.59% 712212 899.39% 2018-04-30
iShares Russell 2000 Growth 1205458 0.96% -- -- 2018-06-14
Delaware Small Cap Core A 650600 0.49% 44700 7.38% 2018-01-31
CREF Stock R1 644170 0.48% 1043 0.16% 2018-01-31
T. Rowe Price New Horizons 1779563 1.43% -136936 -7.15% 2016-09-30
BlackRock Global Allocation Inv B 1719978 1.38% -313953 -15.44% 2016-10-31
American Century Heritage Inv 1380707 1.11% 795000 135.73% 2016-12-31
Perkins Small Cap Value L 1221277 0.98% 259050 26.92% 2016-12-31
BlackRock Global Allocation Fund 2418317 2.00% 926014 62.00% 2015-07-31
T. Rowe Price Health Sciences Fund 2297219 1.80% -22900 -1.00% 2015-09-30
Baron Small Cap Fund 2000000 1.60% -- -- 2015-09-30
iShares Core S&P Mid-Cap (AU) 1714843 1.40% 2310 0.10% 2015-11-19
T. Rowe Price Institutional Mid-Cap Equi 1378000 1.10% 16000 1.20% 2015-09-30
iShares Russell 2000 (AU) 1323495 1.10% -1668 -0.10% 2015-11-19
Fidelity® Select Health Care Portfolio 1289000 1.00% -- -- 2015-09-30
Janus Venture Fund 1288927 1.00% -- -- 2015-09-30
Janus Triton Fund 3462160 2.80% 483025 16.20% 2015-09-30

Rolf Allan Classon Mr. Rolf A. Classon is Independent Director at Catalent, Inc., Member-Supervisory Board at Fresenius Medical Care Management AG, Member-Supervisory Board at Fresenius Medical Care AG & Co. KGaA, Chairman at Tecan Group AG, Non-Executive Chairman at Hill-Rom Holdings, Inc., Chairman at Hill Rom AB, Chairman at Lappesands Invest AB, Chairman at QleanAir Scandinavia AB, Chairman at Vivacta Ltd. and Senior Advisor at Brown Brothers Harriman Private Equity Group. He is on the Board of Directors at Prometheus RxDx, Inc. and Eurand NV. From October 2002 until July 2004, Mr. Classon was Chairman of the Executive Committee of Bayer HealthCare AG, a subsidiary of Bayer AG. He served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President of Bayer Diagnostics from 1991 to 1995. Prior to 1991, he held various management positions with Pharmacia Corporation. He currently serves as Chairman of the Board of Hill-Rom and served as interim Chief Executive Officer of Hillenbrand Industries from May 2005 to March 2006. He currently serves as Chairman of the Board of Directors of Tecan Group Ltd. and as a member of the Board of Directors of Fresenius Medical Care, Catalent, and Freedom Innovations.He previously served as a director of Millipore Corporation and Prometheus Laboratories until they were acquired. In addition, he served as Non-Executive Chairman of Auxillium Pharmaceuticals which was acquired by Endo Pharmaceuticals in January 2015. He was previously employed as Independent Director & Chairman for several companies. He was also employed as a Executive Vice President by Bayer Corp., President by Pharmacia AB, Operating Partner by Health Evolution Management Co. LLC, and President by Pharmacia Development Co., Inc. Mr. Classon received his Chemical Engineering Certificate from the Gothenburg School of Engineering and a Business Degree from the Gothenburg University.
John R. Chiminski Mr. John R. Chiminski is Chairman, President & Chief Executive Officer at Catalent, Inc. He is on the Board of Directors at Catalent Pharma Solutions, Inc. and HealthCare Institute of New Jersey. Mr. Chiminski was previously employed as President & Chief Executive Officer by GE Healthcare Medical Diagnostics and VP & GM-Global Magnetic Resonance Business by GE Healthcare Ltd. He also served on the board at Graham Packaging Co., Inc., DJO Finance LLC and DJO Global, Inc. He received his undergraduate degree from Michigan State University, a graduate degree from Purdue University and a graduate degree from Kellogg School of Management.
John J. Greisch John J. Greisch is a businessperson who has been at the helm of 9 different companies and occupies the position of Chairman at Viant Medical LLC, Chairman of Viant Medical Holdings, Inc., Chief Executive Officer at Advanced Respiratory, Inc. and President at Hill-Rom, Inc. Mr. Greisch is also on the board of 6 other companies. In the past John J. Greisch held the position of President, Chief Executive Officer & Director at Hill-Rom Holdings, Inc. and President of Aspen Surgical Products, Inc. (a subsidiary of Hill-Rom Holdings, Inc.), President-International & Vice President at Baxter International, Inc. and President-International Operations at Baxter BioScience Corp. (a subsidiary of Baxter International, Inc.), President & Chief Executive Officer for FleetPride, Inc. and President, Chief Financial Officer & Treasurer at Interlake Corp. John J. Greisch received a graduate degree from Northwestern University and an undergraduate degree from Miami University.
J. Martin Carroll J. Martin Carroll is on the board of Mallinckrodt Plc, TherapeuticsMD, Inc., Catalent, Inc. and Mallinckrodt Pharmaceuticals. In his past career he occupied the position of Executive VP-Customer Marketing & Sales at Merck & Co., Inc., Chairman of Inotek Pharmaceuticals Corp., President & Chief Executive Officer for Boehringer Ingelheim Pharmaceuticals, Inc., President & Chief Executive Officer at Boehringer Ingelheim Corp. and Global Head-Strategy & Development at Boehringer Ingelheim GmbH. J. Martin Carroll received an undergraduate degree from Holy Cross College (Indiana) and an MBA from Babson College.
Steven L. Fasman Steven L. Fasman is President of Pneumo Abex LLC, Secretary, Senior Vice President & General Counsel at Catalent, Inc. and Senior Vice President & General Counsel for Catalent Pharma Solutions, Inc. He is also on the board of Juniper Pharmaceuticals, Inc. and Catalent Micron Technologies Ltd. and President & Trustee at Jewish Board of Family & Children's Services, Inc. In his past career he held the position of Principal at Paul Weiss, Executive Vice President-Law at MacAndrews & Forbes Holdings, Inc. and Senior VP, Chief Legal & Compliance Officer at M&F Worldwide Corp. Mr. Fasman received a graduate degree from Yale University and an undergraduate degree from Princeton University.
John R. Chiminski John R. Chiminski occupies the position of Chairman & Chief Executive Officer for Catalent, Inc. and President, Chief Executive Officer & Director at Catalent Pharma Solutions, Inc. Mr. Chiminski is also on the board of HealthCare Institute of New Jersey. Mr. Chiminski previously was President & Chief Executive Officer of GE Healthcare Medical Diagnostics and VP & GM-Global Magnetic Resonance Business at GE Healthcare Ltd. He received an undergraduate degree from Michigan State University, a graduate degree from Purdue University and a graduate degree from Kellogg School of Management.
Jack L. Stahl Jack L. Stahl is a businessperson who has been the head of 6 different companies is on the board of United Natural Foods, Inc. and 4 other companies. In the past he was Chairman of New Avon LLC, President & Chief Operating Officer for The Coca-Cola Co., President for The Americas Group, Auditor at Arthur Andersen LLP, President & Chief Executive Officer at Revlon, Inc. and Director at United Negro College Fund, Inc. Jack L. Stahl received an undergraduate degree from Emory University and an MBA from The Wharton School of the University of Pennsylvania.
Donald E. Morel Currently, Donald E. Morel occupies the position of Chairman at The American Oncologic Hospital. Dr. Morel is also Chairman at The Franklin Institute and on the board of 5 other companies. In his past career Dr. Morel occupied the position of Chairman for West Pharmaceutical Services, Inc. Donald E. Morel received an undergraduate degree from Lafayette College and a doctorate and a graduate degree from Cornell University.
Gregory T. Lucier Gregory T. Lucier is a businessperson who has been the head of 10 different companies and presently is Chairman of Epic Sciences, Inc., Chairman for NuVasive, Inc., Chief Executive Officer of Corza Health, Inc. and Chairman of Invuity, Inc. He is also Chairman at Sanford Burnham Prebys Medical Discovery Institute and on the board of 5 other companies. Gregory T. Lucier previously occupied the position of Chairman of BIOCOM, Principal at General Electric Co. President & Chief Executive Officer at GE Medical Systems Information Technologies, Inc. President at GE Harris Railway Electronics, Vice President-Global Services at GE Medical Systems, Inc. and President-Medical Information Technologies at GE Healthcare, Inc. (which are all subsidiaries of General Electric Co.), Chairman & Chief Executive Officer for Invitrogen Corp. and Chairman & Chief Executive Officer at Life Technologies Corp. He received an undergraduate degree from The Pennsylvania State University and an MBA from Harvard Business School.
James A. Quella Mr. James A. Quella is on the Board of Directors at FGL Holdings, Michaels Cos., Inc., DJO Global, Inc., Catalent Pharma Solutions, Inc., Catalent, Inc., Freescale Semiconductor, Inc., DJO Finance LLC and GPC Capital Corp. II. Mr. Quella was previously employed as an Independent Director by Lionbridge Technologies, Inc. (Delaware), an Independent Director by Freescale Semiconductor Holdings I Ltd., Senior Managing Director by Blackstone Corporate Private Equity, Senior Managing Director by Blackstone Mezzanine Advisors, Senior Managing Director by The Blackstone Group, Inc., a Managing Director by DLJ Merchant Banking Partners, Senior Consultant by Mercer Management Consulting, Inc., Senior Consultant by Strategic Planning Associates SRL, and Managing Partner by CSFB Private Equity Partners LLC. He also served on the board at Freescale Semiconductor Holdings I Ltd., Vanguard Health Systems, Inc., Michaels Stores, Inc., Houghton Mifflin Harcourt Publishing Co., Intelenet Global Services Pvt Ltd. /United States/, The Nielsen Co. (US) LLC, Graham Packaging Holdings Co., Allied Waste Industries, Inc., HM Publishing Corp., Celanese Corp., Columbia House Co., DeCrane Holdings Co., Merrill Corp., Von Hoffmann Corp., Von Hoffmann Holdings, Inc., Oliver Wyman, Inc., Advanstar Holdings, Inc., Celanese Emulsions GmbH, DeCrane Aerospace, Inc., Freescale Holdings GP Ltd., Graham Packaging Co. LP, Graham Packaging Co., Inc., InteleNet Communications, Inc., Jostens, Inc., Nielsen NV, The Nielsen Co. BV and Vanguard Health Services, Inc. He received his undergraduate degree from The University of Chicago, an undergraduate degree from the University of Wisconsin and an MBA from The University of Chicago Booth School of Business.
Uwe R�0�1�0�9hrhoff Mr. Uwe R�0�1�0�9hrhoff is a President & Chief Executive Officer at Perrigo Co. Plc, an Independent Director at Catalent, Inc., a Chairman at Gerresheimer Glass, Inc., a Chairman at Gerresheimer Momignies SA, a Chairman-Supervisory Board at Gerresheimer Regensburg GmbH, a Chairman-Supervisory Board at Gerresheimer Tettau GmbH, a Chairman at Gerresheimer Shuangfeng Pharmaceutical Glass Danyang Co. Ltd., a Chairman at Gerresheimer Shuangfeng Pharmaceutical Packaging Zhenjiang and a Chief Executive Officer at Gerresheimer Holdings GmbH. He is on the Board of Directors at Catalent, Inc., Corning Pharmaceutical Packaging LLC, Gerresheimer Quer�0�1�0�8taro SA, Kimble Chase Life Science & Research Products LLC, Kl�0�1�0�9ckner & Co. SE and Neutral Glass & Allied Industries Pvt Ltd. Mr. R�0�1�0�9hrhoff was previously employed as a Chief Executive Officer by Gerresheimer AG, a Chief Executive & Financial Officer by Tettauer Glash�0�1�0�4ttenwerke AG, a Vice President-Controlling by Kimble Usa, Inc., a Chairman by Kimble Bomex (Beijing) Labware Co. Ltd., a Chairman by Kimble Bomex Glass Co. Ltd., a Chief Operating Officer by Gerresheimer Group GmbH, and a President & Chief Executive Officer by Kimble Glass, Inc. He also served on the board at Beijing Gerresheimer Glass Co. Ltd. He received his undergraduate degree from Universit�0�1¤t zu K�0�1�0�9ln.
Wetteny Joseph Currently, Wetteny Joseph is CFO, Principal Accounting Officer & Senior VP at Catalent, Inc. and Co-Managing Director at Catalent Germany Holding III GmbH (a subsidiary of Catalent, Inc.) and Co-Managing Director at Catalent Germany Schorndorf GmbH. Mr. Joseph is also on the board of Catalent CTS (Edinburgh) Ltd., Catalent UK Packaging Ltd., Catalent CTS (Wales) Ltd. and Catalent Micron Technologies Ltd. In his past career Mr. Joseph held the position of President-Clinical Supply Services at Catalent Pharma Solutions, Inc. and Controller at Hughes Supply, Inc. Mr. Joseph received a graduate degree and an undergraduate degree from Florida Atlantic University.
John R. Chiminski John R. Chiminski occupies the position of Chairman & Chief Executive Officer for Catalent, Inc. and President, Chief Executive Officer & Director at Catalent Pharma Solutions, Inc. Mr. Chiminski is also on the board of HealthCare Institute of New Jersey. Mr. Chiminski previously was President & Chief Executive Officer of GE Healthcare Medical Diagnostics and VP & GM-Global Magnetic Resonance Business at GE Healthcare Ltd. He received an undergraduate degree from Michigan State University, a graduate degree from Purdue University and a graduate degree from Kellogg School of Management.
John R. Chiminski John R. Chiminski occupies the position of Chairman & Chief Executive Officer for Catalent, Inc. and President, Chief Executive Officer & Director at Catalent Pharma Solutions, Inc. Mr. Chiminski is also on the board of HealthCare Institute of New Jersey. Mr. Chiminski previously was President & Chief Executive Officer of GE Healthcare Medical Diagnostics and VP & GM-Global Magnetic Resonance Business at GE Healthcare Ltd. He received an undergraduate degree from Michigan State University, a graduate degree from Purdue University and a graduate degree from Kellogg School of Management.
Rosemary A. Crane Rosemary A. Crane is on the board of Teva Pharmaceutical Industries Ltd., Unilife Medical Solutions, Inc. and Catalent, Inc. and Member-Foundation Board at The State University of New York. In her past career Ms. Crane occupied the position of President, Chief Executive Officer & Director at STRATA Skin Sciences, Inc., Group Chairman-OTC & Nutritional Group at Johnson & Johnson, President-US Primary Care Division at Bristol-Myers Squibb Co., Partner at Apple Tree Partners, President, Chief Executive Officer & Director at Epocrates LLC and President & Chief Executive Officer for Epocrates, Inc. (Research). She received an MBA from Kent State University (Ohio) and an undergraduate degree from The State University of New York.
Barry B. Littlejohns Presently, Barry B. Littlejohns holds the position of Co-Managing Director at Catalent Germany Schorndorf GmbH. He is also President-Biologics & Specialty Drug Delivery at Catalent, Inc. Mr. Littlejohns previously was Senior VP-Operations & Business Development at Genmab A, Vice President of Cardinal Health, Inc. and Vice President-Commercial Affairs at Sterile Technology Industries, Inc. He received an undergraduate degree from Swindon College.
Carolyn R. Bertozzi Founder of Redwood Bioscience, Inc., Carolyn R. Bertozzi is on the board of Eli Lilly & Co., The Broad Institute, Inc., Catalent, Inc. and Grace Science Foundation and Member of American Chemical Society, Member of National Academy of Sciences, Member of American Academy of Arts & Sciences, Member of Institute of Medicine, Member of American Society for Biochemistry & Molecular Biology, Inc. and Professor at Stanford University. Dr. Bertozzi previously was Director-Molecular Foundry at Lawrence Berkeley National Laboratory and Professor at the University of California, Berkeley. She received an undergraduate degree from Harvard University and a doctorate from the University of California, Berkeley.
Madhavan Balachandran Madhavan Balachandran is on the board of Stevanato Group SpA, uniQure NV, Catalent, Inc. and Fortuna Fix, Inc. In his past career Mr. Balachandran occupied the position of Senior Vice President-Manufacturing at Amgen, Inc., Vice President-Engineering of Glaxo Wellcome, Inc., Principal at Battelle Memorial Institute and Vice President of Puerto Rico USA Citizenship Foundation. Mr. Balachandran received an MBA from East Carolina University, an undergraduate degree from Indian Institute of Technology Bombay and a graduate degree from State University of New York at Buffalo.
Christa Kreuzburg Christa Kreuzburg is on the board of Tecan Group AG and Catalent, Inc. In her past career she was Head-Corporate Strategic Planning at Bayer AG and Head-Bayer Schering Pharma Europe & Canada at Bayer HealthCare AG (a subsidiary of Bayer AG). She received a doctorate from the University of Duisburg-Essen.
Thomas Castellano Presently, Thomas Castellano occupies the position of Investor Relations Contact at Catalent, Inc. He received an undergraduate degree and an MBA from Seton Hall University.
Alessandro Maselli Alessandro Maselli holds the position of President & Chief Operating Officer at Catalent, Inc. He is also on the board of Catalent Pharma Solutions Ltd., Catalent U.K. Swindon Zydis Ltd. and Juniper Pharma Services Ltd. In the past he held the position of Director-Operations at ABB Group. Mr. Maselli received an undergraduate degree and a graduate degree from Universit�0�1�0�2 degli Studi di Roma Tor Vergata.
Madhavan Balachandran Madhavan Balachandran is on the board of Stevanato Group SpA, uniQure NV, Catalent, Inc. and Fortuna Fix, Inc. In his past career Mr. Balachandran occupied the position of Senior Vice President-Manufacturing at Amgen, Inc., Vice President-Engineering of Glaxo Wellcome, Inc., Principal at Battelle Memorial Institute and Vice President of Puerto Rico USA Citizenship Foundation. Mr. Balachandran received an MBA from East Carolina University, an undergraduate degree from Indian Institute of Technology Bombay and a graduate degree from State University of New York at Buffalo.
Scott Gunther Scott Gunther holds the position of Senior Vice President-Quality & Regulatory Affairs at Catalent, Inc. Mr. Gunther received an undergraduate degree from State University of New York at Buffalo and an MBA from Canisius College.
Paul Hegwood Paul Hegwood is President-Clinical Supply Services at Catalent, Inc. Mr. Hegwood received an undergraduate degree from Kettering University and an MBA from the University of Michigan.
Kay Schmidt Kay Schmidt occupies the position of Senior Vice President-Technical Operations at Catalent, Inc. Ms. Schmidt is also Senior Vice President-Technical Operations at Catalent Pharma Solutions, Inc. Ms. Schmidt received an undergraduate degree from Carroll University, Inc. and a graduate degree from the University of Wisconsin-Whitewater.
Peter Zippelius Peter Zippelius is on the board of Catalent, Inc. He received an undergraduate degree from Virginia Polytechnic Institute & State University.
Ricardo Pravda Mr. Ricardo Pravda is a Chief Human Resources & SVP at Catalent, Inc. He received his undergraduate degree from Universidad Argentina de la Empresa and an MBA from Universidad del Salvador.

量化对比

全部评论 3

  • Moderna盘中涨超6%,此前与制药公司Catalent(CTLT.O)达成一项增加新冠疫苗生产的协议。

  • 据英国金融时报:强生公司的供应商Catalent花两周的时间检查疫苗用玻璃瓶,该公司表示将履行疫苗生产承诺。

  • 美国药企Moderna(MRNA.O)和医药公司Catalent合作生产新冠病毒疫苗。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐